$5.040
-0.117 (-2.33%)At close
WVE News
WVE Events
Wave Life Sciences Completes Redomiciliation to Delaware
Wave Life Sciences announced the completion of the redomiciliation process to change the parent company of the Wave group of companies from a Singapore company to a Delaware corporation. The redomiciliation was completed after the close of trading on Friday, August 7, at which time all issued ordinary shares of Wave Life Sciences were exchanged on a one-for-one basis for newly issued shares of common stock of Wave Life Sciences, a Delaware corporation. Wave's equity will continue to trade under the trading symbol of 'WVE' and its newly issued common stock will begin trading on the NASDAQ on Monday, August 10. Wave does not anticipate any material impact to its employees or its day-to-day business as a result of the completion of the redomiciliation.
Wave Life Sciences Q2 Revenue $2.27M, Below Consensus
Reports Q2 revenue $2.27M, consensus $7.1M. "Our second quarter performance reflects disciplined execution across the pipeline," said Paul Bolno, President and Chief Executive Officer at Wave Life Sciences. "We recently initiated dosing in the Phase 2a portion of our INLIGHT trial in obesity. Our Phase 1 clinical data have already demonstrated substantial reductions of fat - particularly harmful visceral fat - without muscle loss, and with the potential for once or twice-yearly dosing. We expect the Phase 2a portion of the INLIGHT trial, in individuals with higher BMI and higher body fat, to demonstrate WVE-007's broad potential to deliver even greater fat loss and improvements in body composition, as well as benefits across additional cardiometabolic biomarkers such as liver fat. In tandem with this progress, we are working expeditiously to initiate Phase 2 trials evaluating WVE-007 in combination with incretins and as post-incretin maintenance; we believe WVE-007 has the potential to transform the current obesity treatment landscape."
Wave Life Sciences Initiates Phase 2a Trial for WVE-007
Wave Life Sciences announced it has initiated the Phase 2a multidose portion of the Inlight trial, a placebo-controlled study evaluating WVE-007, an investigational GalNAc-siRNA, as monotherapy in individuals living with obesity with high BMI and comorbidities. Wave also expects to initiate new clinical trials evaluating WVE-007 as an incretin add-on and as post-incretin maintenance in the second half of 2026.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.